Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 4, 2001, Pages 937-945

  Kang, Song K ^a   Chou, Rachel H ^a,b   Dodge, Richard K ^a   Clough, Robert W ^a   Kang, Hi Sung L ^a   Bowen, M Gray ^a,b   Steffey, Beverly A ^a   Das, Shiva K ^a   Zhou, Su Min ^a   Whitehurst, Arthur W ^b   Buckley, Niall J ^b   Kim, Jay H ^b   Joyner, Raymond E ^b   Sarmina, Ignacio ^b   Montana, Gustavo S ^a   Ingram, Sally S ^a   Anscher, Mitchell S ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Durham Regional Hospital   (United States)

Author keywords

Brachytherapy; Complications; Prostate cancer

Indexed keywords

CATHETERS; PATIENT TREATMENT; RADIOTHERAPY; TOXICITY; TUMORS;

MORBIDITY;

ONCOLOGY;

IODINE 125; PALLADIUM 103;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; DYSURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUSCLE SPASM; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TECHNIQUE; URINARY TRACT DISEASE; URINARY TRACT OBSTRUCTION;

ACUTE DISEASE; ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; LOGISTIC MODELS; MALE; MIDDLE AGED; PALLADIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; URINATION DISORDERS;

EID: 0035879669     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01530-9     Document Type: Article

References (25)

1. The national cancer data base report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S
2. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
3. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer
4. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer; Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores
5. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation
6. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy
7. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma
8. 125I prostate implantation
9. Long-term complications with prostate implants. Iodine-125 vs. Palladium-103
10. 125I prostate implantation
11. Transperineal palladium 103 prostate brachytherapy. Analysis of morbidity and seed migration
12. Quality of life outcomes after brachytherapy for early stage prostate cancer
13. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer
14. Quality of life after permanent prostate implant
15. Complications after prostate brachytherapy in the Medicare population
16. 125Iodine implantation for treatment of clinically localized prostate cancer. 5-year tumor control and morbidity
17. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer
18. Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy; Smaller volumes, less morbidity
19. Temporal resolution of urinary morbidity following prostate brachytherapy
20. Standard vs. conformal radiation therapy for adenocarcinoma of the prostate; No difference
21. Nonparametric estimation from incomplete observations
22. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
23. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma
24. Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy